File No._____

LICENSE AGREEMENT

DDSBC Tool License Agreement

This License Agreement ("Agreement") is made between the undersigned ("Licensee") and AIONCDYN ("Licensor") for the use of the DDSBC tool code.

Terms and Conditions:

1. Grant of License:
The Licensor grants the Licensee a non-exclusive, non-transferable license to use the Software solely for academic and research purposes.

2. Restrictions:
The Licensee shall not distribute, sublicense, sell, or use the Software for any commercial purpose without the prior written consent of the Licensor.

3. Intellectual Property:
The Licensee acknowledges that the Licensor owns all intellectual property rights in the Software.

4. Confidentiality:
The Licensee agrees to keep the Software confidential and not to disclose it to any third party without the Licensor's written consent.

5. Indemnification:
The Licensee agrees to indemnify, defend, and hold harmless the Licensor from and against any claims, liabilities, damages, and expenses arising from the use or distribution of the Software in violation of this Agreement.

6. Termination:
The Licensor reserves the right to terminate this Agreement immediately if the Licensee breaches any terms of this Agreement.

Licensee Information:

Name & Company/Institution: _____

Email: _____

Signature: _____

Licensor Information:

AIONCDYN

Email: iaamirofficial@outlook.com

Please review the Agreement, sign it, and attach it to your email request.

Message from the CEO



At AIONCDYN, our mission is to pioneer the forefront of oncological research through the integration of artificial intelligence and computational structural modeling. We are dedicated to advancing the field of anticancer therapies by leveraging cutting-edge technologies and innovative methodologies.

Our goal is to contribute significantly to the development of novel therapeutic strategies that target cancer with unprecedented precision and efficacy. By harnessing the power of AI, we aim to elucidate complex biological pathways, predict drug interactions, and design optimized therapeutic agents that can revolutionize cancer treatment.

AIONCDYN is committed to pushing the boundaries of what is possible in computational biology. We strive to create a paradigm shift in cancer therapy development by utilizing high-throughput data analysis, machine learning algorithms, and advanced structural modeling techniques. Our research endeavors are focused on accelerating the discovery of potent anticancer compounds and enhancing the therapeutic index of existing treatments.

Through our innovative approaches, AIONCDYN aspires to make a profound impact on the lives of cancer patients worldwide. We believe that our interdisciplinary efforts will lead to breakthroughs that redefine the landscape of cancer therapeutics and offer new hope to those affected by this devastating disease.

Together, we can transform the future of cancer treatment and bring about a new era of precision medicine.

Dr. Aamir Mehmood
CEO, AIONCDYN